Learning About the New Definition of MASLD

Guest: Paul Kwo, MD

Non-alcoholic fatty liver disease connoted that there's no alcohol contribution to the fat and didn't accurately convey the interplay between metabolic-driven cytosis, which can come from insulin resistance and all of the other metabolic dysfunction-associated inflammatory patterns, as well as the contributions of alcohol. So what do we know about patients who have metabolic dysfunction-associated steatotic liver disease (MASLD) and also consume alcohol? To learn more, join Dr. Peter Buch as he discusses this with Dr. Paul Kwo, Professor of Medicine and the Director of Hepatology at Stanford University.